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Abstract 
The serotonin-gated 5-HT3 receptor is a ligand-gated ion channel. Its location at the synapse in the central 
and peripheral nervous system have rendered it a prime pharmacological target, e.g. for antiemetic drugs 
that bind with high affinity to the neurotransmitter binding site and prevent the opening of the channel. 
Advances in structural biology techniques has led to a surge of disclosed three-dimensional receptor 
structures, however, solving ligand-bound high-resolution 5-HT3 receptor structures has not been 
achieved to date. Ligand binding poses in the orthosteric binding site have been largely predicted from 
mutagenesis and docking studies. We report the synthesis of a series of photo-crosslinking compounds 
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whose structures are based on the clinically used antiemetic drug granisetron (Kytril®). These displaced 
[3H]granisetron from the orthosteric binding site with low nanomolar affinities and showed specific 
photo-crosslinking with the human 5-HT3 receptor. Detailed analysis by protein-MS/MS identified a 
residue (Met-228) near the tip of binding loop C as the covalent modification site. 
 
Key Words: 5-HT3 receptor; antagonist; granisetron; photo-crosslinking probe; orthosteric binding site; 
mass spectrometry; docking 
 
Introduction 
The serotoninergic system is involved in the control and regulation of many physiological 
processes such as sleep, appetite, vasoconstriction, body temperature, gastrointestinal motility and mood. 
With respect to the latter, an imbalanced function of the serotoninergic system has been strongly 
associated with depression and mood disorders. Several drugs on the market (e.g. selective serotonin 
reuptake inhibitors, SSRIs), aim to improve this imbalance, albeit with varying success. Serotonin (5-
hydroxytryptamine, 5-HT) is a neurotransmitter that exerts its effect by activating at least fourteen 
different receptors. The large majority of these are metabotropic (5-HT1,2,4-7), while only the 5-HT3 
receptor is ionotropic and responsible for the fast depolarization of neurons.1-3 As such, the 5-HT3 
receptor shares more structural similarities with other members of the Cys-loop ligand-gated ion channel 
family that also includes nicotinic acetylcholine (nACh), γ-amino butyric acid (GABAA/C) and glycine 
receptors. These ion channels consist of five subunits that are pseudo-symmetrically assembled around a 
central ion conducting pore. Each of the five protomers features three structurally distinct domains 
(Figure 1a): the extracellular domain (ECD), the transmembrane domain (TMD) and the intracellular 
domain (ICD). The serotonin binding sites (i.e. orthosteric sites) are located in the ECD at the interface of 
two adjacent protomers, formed by the convergence of three peptide loops from one protomer (the 
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principal face, loops A-C) and three loops from the neighboring protomer (the complementary face, loops 
D-F, Figure 1c).4  
 
Figure 1. (a) View parallel to the plasma membrane of the mouse 5-HT3A receptor (PDB ID: 4PIR) with 
the extracellular (ECD), transmembrane (TMD) and intracellular (ICD) domains indicated. The 
stabilizing nanobodies have been omitted for clarity. The approximate location of the lipid bilayer is 
shown by horizontal dotted lines. Two adjacent protomers forming one orthosteric binding site (black 
box) are highlighted. (b) Extracellular view perpendicular to the plasma membrane of the receptor with 
one orthosteric binding site (black box) indicated. (c) Close up view of one orthosteric binding site 
showing the principal face (blue, loops A-C) and complementary face (yellow, loops D-F). (d) Chemical 
structures of endogenous agonist serotonin and prototypical competitive antagonist granisetron (Kytril®). 
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A class of high-affinity antagonists (the ‘setrons’) that compete with serotonin for the orthosteric 5-
HT3 receptor binding sites has been established as anti-emetic drugs in the clinic, alleviating the 
symptoms of nausea and vomiting resulting from chemo-, radiotherapy and general anaesthesia.3 
Pharmacological antagonism of 5-HT3 receptors is also used to treat irritable bowel syndrome (IBS). 
Recent reports indicate, however, that partial 5-HT3 receptor agonism might be a better approach to treat 
certain types of IBS, as a large group of patients suffer from significant side effects during the current 
antagonist treatment.5 Other disorders where 5-HT3 receptors might be involved include depression, drug 
abuse, schizophrenia, fibromyalgia, pruritus, bulimia nervosa and pain.6-8 
Detailed structural information about the 5-HT3 receptor binding sites would be very beneficial for 
the development of novel compounds to improve current therapies and establish new therapies in other 
disease areas. A wealth of mutagenesis studies in the past three decades have probed putative binding site 
residues that often have been deduced from a combination of homology modelling and docking.9-11 These 
and other studies have identified residues that are important for ligand binding and/or channel gating, 
although extracting detailed non-covalent interactions between functional groups of the ligand and 
receptor residues is very challenging. Four years ago the first crystal structure of a mammalian 5-HT3 
receptor was presented (Figure 1).12 The truncated form of the homomeric mouse 5-HT3A receptor was 
stabilized with nanobodies and its structure solved to a resolution of 3.5 Å (PDB ID: 4PIR). In this apo 
structure, the recognition loops of the nanobodies reach into the orthosteric binding site. More recently, 
the cryo-EM structure of the full length mouse apo-5-HT3A receptor at 4.3 Å resolution was published 
(PDB ID: 6BE1).13 In a different approach, pentameric acetylcholine binding protein (AChBP), that is 
homologous to the ECD, was engineered to bind agonists and antagonists with affinities comparable to 
the 5-HT3 receptor (termed 5HTBP). One such construct was co-crystallized with competitive antagonist 
granisetron (PDB ID: 2YME)14 and with picomolar-affinity antagonist palonosetron (PDB ID: 5LXB),15 
and the complexes were solved to high resolution (2.4 Å and 2.3 Å, respectively). These models have 
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revealed very detailed non-covalent interactions, such as hydrogen bonds, hydrophobic, π-π and cation-π 
interactions, between the ligands and binding site residues. Nevertheless, one has to exercise caution 
when using these binding site models to predict binding orientations of structurally similar ligands at the 
receptor.16  
Using photo-crosslinking probes is a well-established technique to capture weak non-covalent 
interactions between a small molecule and its target protein. In the Cys-loop receptor family, orthosteric 
and allosteric binding sites on nACh and GABA receptors have been investigated by utilizing photo-
crosslinking probes, derived from general anesthetics, insecticides and other modulators, in conjunction 
with protein sequence analysis after labelling (e.g. MS).17-24 Moreover, covalent labelling can also be 
utilized to map the binding site(s) of a ligand or to identify the cellular target(s) if unknown. Photo-
crosslinking moieties such as diazirines, benzophenones and phenylazides that are appended to a tolerant 
position of the bioactive molecule are most commonly employed.25,26 The photo-crosslinking 
methodology is applicable to native, wild type proteins and if the design of the probe is chosen 
appropriately (e.g. by using a modifiable linker or additional bioorthogonal functional groups) the target 
protein can be functionalized further with new properties by way of post-photoaffinity modification (P-
PALM).27,28 However, only a few photo-crosslinking studies have been conducted with 5-HT3 receptors. 
For instance, Blanton and co-workers have employed the lipophilic, well-known photolabel [125I]TID (3-
trifluoromethyl-3-(m-[125I]iodophenyl)diazirine) to covalently modify receptor residues at the lipid-
protein interface.29 Earlier studies by Lummis and Baker have also shown that intrinsically photo-reactive 
antipsychotic phenothiazines label the 5-HT3 receptor orthosteric binding site, however, a detailed post-
labelling sequence analysis was not performed.30 Therefore, detailed structural information from photo-
labelling could be beneficial for understanding the binding of ligands at these receptors. 
We have previously developed fluorescent31-33 and PET34 5-HT3 receptor ligands derived from the 
high-affinity, competitive antagonist granisetron (Kytril®, Figure 1d) and used these probes to study 
these receptors in cells and live animals. Here we extend these studies of biophysical probes by 
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synthesizing a series of photo-crosslinking probes that were created by appending various photo-reactive 
moieties to three different positions of the granisetron core. Furthermore, we use these probes to 
specifically photo-label residues in the orthosteric binding site of the 5-HT3 receptor. 
 
Results and Discussion 
Design and Synthesis of 5-HT3 Receptor Photo-crosslinking Probes 
Following our previous SAR study of granisetron35 and design of fluorescent granisetron probes31,32 
we chose to link the photo-labelling moieties to the indazole N-1, C-7 or granatane N-9’ position of the 
antagonist core (Scheme 1). Briefly, either 1H-indazole amide 135 or 7-hydroxyindazole amide 731,35 were 
alkylated with protected linkers, followed by deprotection and subsequent alkylation with benzophenone 
bromide 1736 or diazirine benzyl bromide 19,37 or amidation with diazirine benzoic acid 20.38,39 For 
accessing the N-9’ modified probes 15 and 16, Boc-protected granatane amine 1240 was alkylated first 
with diazirine benzyl iodide 21,41,42 deprotected, coupled to 1H-indazole-3-carboxylic acid and finally N-1 
alkylated. 
We have also synthesized two granisetron probes 6 and 16 that, in addition to the photo-labelling 
moieties, contain an alkyne handle to aid post-photoaffinity identification of modified receptors by means 
of Cu(I)-catalysed alkyne-azide cycloaddition (CuAAC) reactions. Granisetron probe 6 was obtained 
through amidation of precursor 335 with benzophenone acid 1843,44 and 16 was synthesized by N-1 
propargylation of indazole amide 14.  
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Scheme 1. Synthesis of granisetron-based photo-crosslinking probes. Reagents and conditions: (a) 
KOtBu, THF/DMF 5:1, 0°C; either Br(CH2)3OTBS or Br(CH2)3NHBoc, rt, 68% (R
1 = OTBS), 78% (R1 = 
NHBoc). (b) For R1 = OTBS: TBAF, THF, rt, 86% 2. For R1 = NHBoc: 1.2M HCl in MeOH, rt, 98% 3. 
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(c) 2, NaH, THF/DMF 5:1, 0°C; 17, rt, 27%. (d) 3, 20, Et3N, HATU, DMF/DCM 3:2, rt, 24%. (e) 18, 
SOCl2, MeCN, 80°C; 3, DCM, 0°C to rt, 11%. (f) KO
tBu, THF/DMF 5:1, 0°C; either Br(CH2)2OTBS or 
Br(CH2)3OTBS, rt, 78% (n = 1), 34% (n = 2). (g) TBAF, THF, rt, 51% 8 (n = 1), 85% 9 (n = 2). (h) 9, 
NaH, THF/DMF 5:1, 0°C; 17, rt, 20%. (i) 8, NaH, THF/DMF 5:1, 0°C; 19, rt, 35%. (j) K2CO3, 21, EtOH, 
55°C, 82%. (k) TFA, DCM, rt, quant. (l) 1H-indazole-3-carboxylic acid, DCC, HOBt, DCM/DMF 3:2, rt; 
13, 66%. (m) 14, KOtBu, THF/DMF 4:1, 0°C; MeI, rt, 88%. (n) 14, Cs2CO3, DMF, rt; 3-bromoprop-1-
yne, 93%. See structure 1 for the numbering of the granisetron core. 
 
Pharmacological Characterization of 5-HT3 Receptor Photo-crosslinking Probes 
The binding affinities of the granisetron photo-crosslinking probes 4-6, 10, 11, 15 and 16 for the 
human homopentameric 5-HT3A receptor were assessed by competition with [
3H]granisetron. The Ki 
values are summarized in Table 1.  
All probes except 15 and 16 exhibited a sub-nanomolar to low nanomolar affinity at the orthosteric 
binding site of the 5-HT3A receptor. This is in line with our previous findings where appendage of bulky 
fluorescent dyes to the indazole N-1 and C-7 positions resulted in high-affinity orthosteric ligands (for the 
numbering of the granisetron core see structure 1, Scheme 1).31,32,35 Although 15 and 16 compete with 
[3H]granisetron for the same binding site, their affinities are three orders of magnitude lower than the 
parent ligand. Previously we synthesized N-9’-benzyl granisetron35 that similarly had a lower affinity (pKi 
= 6.72 ± 0.24, Ki = 191 nM, n = 6)
16 than the parent ligand and thus it seems that further substitution at 
the para-position of the phenyl ring is less favorable. 
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Table 1. Binding Affinities of Granisetron Photo-crosslinking Probes at Human 5-HT3A Receptor
 
Compound pKi
a
 Ki (nM) n 
Granisetron - 1.45b 3 
4 10.21 ± 0.38 0.06 4 
5 8.26 ± 0.04 5.50 4 
6 7.48 ± 0.16 33.1 5 
10 9.34 ± 0.11 0.46 4 
11 8.22 ± 0.28 6.03 3 
15 5.67 ± 0.14 2138 7 
16 5.99 ± 0.22 1023 3 
 
aData are the mean of n independent experiments ± SEM and determined from competition binding with 
[3H]granisetron using HEK293 cell membranes stably expressing 5-HT3AR. 
bReference 45. 
 
Photo-crosslinking of 5-HT3 Receptor with Granisetron Probes 
Whole cell lysate from HEK293T cells stably expressing human N-terminal FLAG-tagged 5-HT3A 
receptor32 was incubated with either 6, 16 or non-specific alkyne benzophenone 22 (Figure 2), irradiated 
(at 302 nm for 30 min) and subsequently treated with biotin azide 23 (Figure 2) under CuAAC conditions 
(CuSO4, TBTA, TCEP). Biotinylated proteins were pulled down with streptavidin beads, eluted and 
analyzed by Western blot. Whereas clear biotinylated bands could be observed for 6 in the right mass 
region for the 5-HT3A receptor (calc. 57.4 kDa for one protomer, exact sequence see Figure S3), photo-
crosslinking with probe 16 resulted in almost no bands (Figure S1). This could be due to the significantly 
lower binding affinity of 16 compared to 6 (Table 1) or that differing binding orientations result in 
different photo-crosslinking and biotin labelling efficacies. Benzophenone 22, that is lacking the 
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granisetron moiety did not give significant photo-crosslinking bands, consistent with its lack of 
competition with [3H]granisetron. 
   
   
   
a b 
c d 
e f g 
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Figure 2. Photo-crosslinking of FLAG-tagged h5-HT3A receptor with granisetron probe 6 and control 
probe 22. Irradiation of samples was followed by CuAAC reaction with biotin azide 23 and pull down 
with streptavidin beads. FLAG was visualized with rabbit α-FLAG/donkey α-rabbit-IRDye 680CW (red), 
biotin with streptavidin-800CW (green) on Western blots. Left panels show overlay of red and green 
channel detection, right panels are grayscale pictures of green channel (biotin) of the same gel. 5-HT3R: 
purified, non-irradiated FLAG-tagged h5-HT3A receptor for reference; band between 50 and 60 kDa 
corresponds to one protomer (ca. 57 kDa), band at higher molecular weight is glycosylated protomer or 
dimer.32 Wash: supernatant after incubation with streptavidin beads. Elution: sample after elution from 
streptavidin beads. (a, b) Irradiation of purified, micelle-solubilized h5-HT3A receptor in the presence of 
different concentrations of 6, 22 (from left to right: 2.5 µM, 250 nM, 25 nM, 2.5 nM) or no compound. 
Biotinylated protein band below 50 kDa was not identified. (c, d) Competition of granisetron (gran) with 
6 significantly diminishes formation of photo-crosslinked 5-HT3 receptor. (e, f) 6 photo-crosslinks 5-HT3 
receptor in the plasma membrane of HEK293T cells. (g) Structures of compounds used. 
 
Affinity-purified human FLAG-tagged 5-HT3A receptor reconstituted in C12E9 micelles
32 was 
incubated with varying concentrations of granisetron probe 6 or benzophenone alkyne 22 (2.5 µM – 2.5 
nM), irradiated and clicked with biotin azide 23. Clear, concentration-dependent biotinylated bands at 
around 60 kDa could be observed for 6 but not for non-binder 22 (Figures 2a and 2b). Whilst photo-
crosslinking with 25 nM 6 still gave a distinct band for biotinylated 5-HT3A receptor (Figure 2b, lane 3), 
no such band was observed at 2.5 nM 6 (Figure 2b, lane 4), consistent with this being well below its Ki of 
33 nM (Table 1). Blocking the receptor orthosteric binding sites with granisetron prior to incubation with 
6 and irradiation reduced the formation of biotinylated 5-HT3A receptor bands on the Western blot 
(Figure 2d, lane 1 vs. 2). Similar to our results from whole-cell lysates, benzophenone 22 gave very little 
non-specific photo-crosslinking bands in the presence or absence of granisetron (Figure 2d, lanes 3 and 
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4). The amount of labelling by 6 in the presence of competitor granisetron was comparable to levels of 
labelling observed by benzophenone alkyne 22 (Figure 2d, lanes 2-4). 
The photo-crosslinking of the 5-HT3A receptor by 6 and 22 was also studied in the plasma 
membrane of live HEK293T cells stably expressing the FLAG-tagged construct. Cell viability was 
regularly checked by automated counting throughout the irradiation period (25 min at 302 nm and 0°C) 
and did not change (Figure S2). After affinity purification of the 5-HT3A receptors using FLAG-beads, 
they were reacted with biotin azide 23 under CuAAC conditions and analyzed by Western blot (Figures 
2e and 2f). With 6, a distinct biotinylation band was detected in the mass region for one 5-HT3A receptor 
protomer (Figures 2e and 2f, lane 3), while 22 gave very weak biotinylation background signals, 
consistent with our experiments with purified receptors in micelles (Figure 2f, lane 2). 
 
Mass Spectrometry Analysis of Photo-crosslinked Sites 
Affinity-purified FLAG-tagged human 5-HT3A receptor
32 was run on a SDS-PAGE gel, stained 
with Coomassie and the band at around 57 kDa was excised. Digestion of the excised band with trypsin 
followed by mass spectrometry analysis of the resulting peptide fragments gave a sequence coverage of 
51% (Figure S3) with the hydrophobic transmembrane sequences TM1-TM4 being particularly difficult 
to ionize and detect. Optimization of the digestion protocols by also utilizing proteinase K, aspartase N 
and endoproteinase LysC allowed the identification of 78% of the whole receptor sequence and 91% of 
the 5-HT3 receptor ECD (Figure S3). This includes almost full sequence coverage of the orthosteric 
binding loops A-F (Figure 1). 
Having established suitable experimental conditions for labelling 5-HT3 receptors, photo-
crosslinking was also attempted using probes 4, 5, 10, 11 and 15. After incubation and irradiation, 
Coomassie-stained bands of appropriate receptor protomer mass were excised from SDS-PAGE gels and 
digested using the previously optimized protocols. For 4 and 10, mass spectrometry revealed the fragment 
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225EFSMESSNYYAEMK238 (loop C, Figures 1c and S3) had the mass shift that corresponds to the 
covalent modification with the probes. Further fragmentation of this peptide by MS/MS identified Met-
228 as the primary site of crosslink (Figures 3 and S4). In both cases, the peak at m/z 138.13, stemming 
from the fragmentation of the 9-methyl-9-azabicyclo[3.3.1]nonane (granatane) moiety of 4 and 10 (Figure 
S5), could be clearly detected (Figures 3b and 3c, inset). Met-228 is located close to the tip of loop C of 
the orthosteric binding site (Figures 1c and 4), in line with our experimental evidence that both 4 and 10 
compete for the same binding site as [3H]granisetron with high affinity (Table 1). 
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Figure 3. Identification of labelling site. Untreated (a) or probe-treated (b, c) human 5-HT3A receptor was 
digested with LysC/trypsin, the resulting peptides detected by LC-MS/MS and analyzed by Sequest HT 
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(v1.3). Most peaks could be assigned to the y ion series of loop C (Glu-225 to Lys-238). (a) MS/MS 
spectrum of m/z 858.35 (unmodified peptide 225EFSMESSNYYAEMK238, z = +2). (b) MS/MS spectrum 
of m/z 756.00 (photo-crosslinked peptide 225EFSM(4)ESSNYYAEMK238, z = +3). Inset: Enlarged region 
of the spectrum showing the diagnostic C9H16N
+ fragment (m/z 138.13) originating from the 9-methyl-9-
azabicyclo[3.3.1]nonane (granatane) moiety of the granisetron probes (Figure S5). (c) MS/MS spectrum 
of m/z 766.00 (photo-crosslinked peptide 225EFSM(10)ESSNYYAEMK238, z = +3). Inset: Enlarged region 
of spectrum. Note how in spectra (b) and (c) the y ion series is interrupted at Met-228 by the covalent 
modification with the probes. 
 
Molecular Modelling 
Based upon the experimental findings that 4 and 10 competitively displace [3H]granisetron and 
crosslink with Met-228 of loop C we sought a computational approach to predict possible binding 
orientations of the two probes in the orthosteric 5-HT3 receptor binding site. We used the high-resolution 
5HTBP structure (PDB ID: 2YME) as docking template as (i) it has been mutated to mimic the human 5-
HT3 receptor binding site, (ii) the orientation of granisetron in 5HTBP is known to correctly represent the 
orientation found in the native 5-HT3 receptor
16 and, (iii) it was co-crystallized with granisetron which is 
the same recognition moiety of our probes. For the purpose of validation, granisetron was docked (FRED 
v2.1) into this binding site model and its predicted orientation was found to be similar to the binding pose 
in the crystal structure (Figure S6a). Probes 4 and 10 were also docked into the same site without 
restraints and resulted in the predicted binding orientations shown in Figures 4 and S7. 
In light of experimental evidence, such as mutagenesis and the pharmacophore model for 
competitive 5-HT3 receptor antagonists, we prefer the orientations shown in Figure 4. For both 4 and 10 
the granisetron moiety is located in the middle of the orthosteric binding site between loops B, C 
(principal face), D and E (complementary face). The azabicyclic moiety is pointing towards the centrally 
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located loop B residue Trp-145 (Trp-183 in 5-HT3 receptor, Figure S6b). This highly conserved residue 
can form cation-π interactions with ammonium groups46,47 and is known to influence the binding of 
several other orthosteric 5-HT3 receptor ligands.
48 Overall, the granisetron portion of 4 and 10 broadly 
occupies a similar position and orientation as co-crystallized granisetron in 5HTBP (green sticks, Figure 
4). The benzophenone photo-crosslinking group is near the tip of loop C with the carbonyl carbon within 
short distance of the side chain of Ser-187 that aligns with Met-228 in the 5-HT3 receptor (Figure S6b). 
The carbonyl group of benzophenones converts into a ketyl radical upon irradiation, which can rapidly 
react with nearby C-H bonds forming covalent connection.25 It should be noted that although the 
orientations in these dock-poses are compelling, to confirm the poses requires further experimental 
validation. Ultimately, probes 4 and 10 are photo-crosslinking conjugates of granisetron and caution may 
be needed when predicting binding orientations for other ligands from the poses that are shown.16 
a b 
  
Figure 4. Proposed binding orientations of photo-crosslinking probes (a) 4 (deep pink sticks) and (b) 10 
(cyan sticks) in the 5HTBP orthosteric binding site. Ligand poses shown are representative of clusters of 
generated docking solutions (4: 3/10, 10: 2/10 of generated docking solutions) that are the most consistent 
with evidence from mutagenesis and the pharmacophore model for 5-HT3 receptor ligands.
14,16,47 The 
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peptide chain of the principal face (left) is shown in white and of the complementary face (right) in gray. 
Granisetron co-crystallized with 5HTBP (PBD ID: 2YME) is shown as reference (green sticks). Side 
chains of residues Trp-145 and Ser-187 discussed in the text are highlighted as ball-and-sticks. The latter 
residue aligns with Met-228 of the 5-HT3 receptor (Figure S6b) that was identified as crosslinking site by 
MS studies (Figure 3). Black asterisk denotes the carbonyl carbon of the benzophenone photo-
crosslinking moiety of 4 and 10. For alternative predicted binding orientations of 4 and 10 see Figure S7.  
 
Conclusions 
We synthesized nanomolar affinity photo-crosslinking probes that bind to the 5-HT3 receptor 
orthosteric binding site. Our results demonstrate that the granisetron scaffold is suitable for the attachment 
of large biophysical tags, in particular at indazole positions N-1 and C-7. With these probes, we were able 
to specifically photo-label the receptor at Met-228 which is located near the tip of loop C. Our study also 
provides design clues for crosslinking probes with cleavable linkers that can be used for post-
photoaffinity labelling modifications with reagents such as biotin.27,28 Here we achieved this in both 
purified and native receptors providing an opportunity to introduce other biophysical reporters (e.g. small 
fluorescent dyes) to the tip of the highly mobile binding loop C. 
 
Methods 
Chemistry. For general synthesis methods, synthesis of photo-crosslinking moieties 18, 20, 21 and 
protected linkers see the Supporting Information. The synthesis of 1, 3 and 7 was described 
previously.31,35 Protected granatane 1240 and photo-crosslinking moieties (17,36 1937) were obtained 
according to literature procedures, with slight modifications (Supporting Information). 
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1-(3-Hydroxypropyl)-N-((1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1H-indazole-3-
carboxamide (2). A suspension of indazole amide 135 (300 mg, 1.01 mmol) in THF/DMF 5:1 (15 mL) 
was cooled to 0°C. KOtBu (124 mg, 1.20 mmol) was added as suspension in dry THF (2 mL) and the 
mixture was stirred at 0°C for 15 min. (3-bromopropoxy)(tert-butyl)dimethylsilane (382 mg, 1.51 mmol) 
was dissolved in dry THF (2 mL) and added to the reaction mixture. Cooling was removed and the 
mixture stirred at RT overnight. Solvents were removed in vacuo, the residue taken up in H2O (10 mL) 
and the aqueous mixture extracted with EtOAc (3 x 20 mL). Drying the organic layers over Na2SO4 and 
evaporation of the solvent under reduced pressure gave crude, TBS-protected indazole (322 mg, 68%) as 
colorless crystals. 1H-NMR (300 MHz, CDCl3) δ 8.39 (d, J = 8.1, 1H), 7.50 – 7.32 (m, 2H), 6.78 (d, J = 
7.6, 1H), 4.66 – 4.37 (m, 3H), 3.77 – 3.48 (m, 2H), 3.10 (d, J = 10.1, 2H), 2.64 – 2.42 (m, 5H), 2.23 – 
2.04 (m, 2H), 1.99 (br, 3H), 1.55 – 1.50 (m, 1H), 1.44 – 1.33 (m, 2H), 1.06 (d, J = 9.1, 2H), 0.93 (s, 6H), 
0.05 (s, 9H). MS (NSI) m/z 471.31, [M+H]+. 
TBS-protected indazole from above (300 mg, 0.64 mmol) and TBAF (335 mg, 1.28 mmol) were 
dissolved in THF (1.5 mL) and stirred overnight at RT. H2O (8 mL) was added and the mixture extracted 
with DCM (3 x 20 mL). The combined organic layers were washed with H2O (10 mL), dried over Na2SO4 
and evaporated. After purification with flash chromatography (silica gel, gradient DCM 100% to 
DCM/MeOH/Et3N 96:3:1), title compound 2 was obtained as clear oil (196 mg, 86%). 
1H-NMR (300 
MHz, CDCl3) δ 8.38 (d, J = 8.2, 1H), 7.51 – 7.38 (m, 2H), 7.30 – 7.23 (m, 1H), 6.92 (s, 1H), 4.67 – 4.58 
(m, 1H), 4.56 (t, J = 6.7, 2H), 3.63 (t, J = 5.8, 2H), 3.22 (d, J = 12.0, 2H), 2.61 (s, 3H), 2.60 – 2.50 (m, 
2H), 2.25 – 2.14 (m, 2H), 2.12 – 1.96 (m, 3H), 1.71 – 1.54 (m, 3H), 1.30 – 1.08 (m, 2H). HRMS m/z 
calcd for C20H29N4O2 [M+H]
+ 357.2285, found 357.2289. 
1-(3-((4-Benzoylbenzyl)oxy)propyl)-N-((1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-
1H-indazole-3-carboxamide (4). Alcohol 2 (33.4 mg, 93 µmol) was dissolved in anhydrous THF/DMF 
5:1 (6 mL) and cooled to 0°C. NaH (8.3 mg, 208 µmol, 60% in oil) was added and stirring at 0°C was 
continued for 5 min. Benzophenone bromide 17 (28.4 mg, 103 µmol) was added, the cooling removed 
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and the suspension stirred at RT overnight. As reaction control by TLC still showed starting alcohol 2, 
more NaH (10.8 mg, 270 µmol, 60% in oil) and bromide 17 (24 mg, 87 µmol) was added at RT and 
stirring of the red solution was continued at RT overnight. The solvents were removed in vacuo and the 
residue first purified by flash chromatography (alumina, DCM) and then by prepTLC (silica gel, 
DCM/MeOH/Et3N 96:3:1). To remove traces of Et3N the product was taken up in little H2O and extracted 
with DCM. Drying the DCM layer over Na2SO4 and evaporation gave 4 (13.9 mg, 27%). UV/Vis (PBS 
buffer): λmax abs. 264 nm. IR: 2925, 2850, 1657, 1530, 1309, 1278, 1176, 1104, 924, 733, 704 cm
-1. 1H-
NMR (300 MHz, CDCl3) δ 8.38 (d, J = 8.1, 1H), 7.84 – 7.76 (m, 4H), 7.64 – 7.55 (m, 1H), 7.53 – 7.34 
(m, 7H), 7.27 (m, 1H), 6.85 (d, J = 8.1, 1H), 4.66 – 4.47 (m, 5H), 3.44 (t, J = 5.7, 2H), 3.17 (d, J = 10.5, 
2H), 2.63 – 2.45 (m, 5H), 2.33 – 2.22 (m, 2H), 2.07 – 1.93 (m, 3H), 1.63 – 1.43 (m, 3H), 1.14 (d, J = 9.0 
Hz, 2H). 13C-NMR (75 MHz, CDCl3) δ 196.5, 162.3, 143.1, 141.4, 137.8, 137.1, 132.6, 130.5, 130.2, 
128.5, 127.3, 126.9, 123.2, 122.9, 122.7, 109.3, 77.4, 72.7, 67.2, 51.8, 46.1, 40.8, 40.6, 32.6, 30.1, 25.1, 
14.2. HRMS m/z calcd for C34H39N4O3 [M+H]
+ 551.3017, found 551.3011. 
N-((1R,3r,5S)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1-(3-(4-(3-(trifluoromethyl)-3H-
diazirin-3-yl)benzamido)propyl)-1H-indazole-3-carboxamide (5).
39 Amine 335 (28.4 mg, 66 µmol) was 
dissolved in dry DMF/DCM 3:2 (5 mL) and then carboxylic acid 20 (15.3 mg, 66 µmol), HATU (50.4 
mg, 133 µmol) and three drops of Et3N were added. The reaction mixture was stirred at RT overnight. 
Solvents were removed under reduced pressure and the brown residue was taken up in sat. aq. NaHCO3 
(15 mL) and extracted with DCM (3 x 15 mL). The crude oil obtained after evaporation of the organic 
layers was purified by prepTLC (silica gel, DCM/MeOH/Et3N 96:3:1). The product still contained some 
Et3N which was removed by dissolving in sat. aq. NaHCO3 (2 mL) and extracting with DCM (3 x 2 mL). 
The DCM layers were dried (Na2SO4) and evaporated to yield probe 5 (9 mg, 24%) as slightly yellow oil. 
UV/Vis (PBS buffer): λmax abs. 302 nm. IR: 2924, 1650, 1538, 1345, 1310, 1231, 1154, 940, 842, 743 
cm-1. 1H-NMR (300 MHz, CDCl3) δ 8.10 (d, J = 8.1, 1H), 8.01 (d, J = 8.4, 1H), 7.70 (d, J = 8.4, 2H), 7.41 
– 7.26 (m, 2H), 7.16 – 7.06 (m, 3H), 6.76 – 6.68 (m, 1H), 4.82 (s, 1H), 4.34 (t, J = 6.5, 2H), 3.67 (d, J = 
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9.1, 2H), 3.48 – 3.35 (m, 2H), 2.86 (s, 3H), 2.62 (t, J = 15.3, 2H), 2.28 – 2.12 (m, 3H), 2.12 – 1.86 (m, 
4H), 1.51 (d, J = 13.5, 2H), 1.30 – 1.20 (m, 1H), 0.77 (d, J = 7.5, 2H). 13C-NMR (75 MHz, CDCl3) δ 
192.2, 166.6, 162.7, 140.8, 137.0, 129.9, 127.5, 127.0, 126.5, 126.1, 122.8, 122.7, 122.2, 109.3, 77.2, 
53.5, 46.7, 38.9, 37.6, 30.5, 29.7, 29.0, 24.5, 12.0. HRMS m/z calcd for C29H33F3N7O2 [M+H]
+ 568.2642, 
found 568.2621. 
N-((1R,3r,5S)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1-(3-(4-(4-(prop-2-yn-1-
yloxy)benzoyl)benzamido)propyl)-1H-indazole-3-carboxamide (6). Acid 18 (67 mg, 0.24 mmol) was 
suspended in MeCN (5 mL) and SOCl2 (128 mg, 1.08 mmol) was added. The mixture was stirred at 80°C 
for 3 h and then at RT overnight. Volatiles were removed in vacuo, the brown residue was redissolved in 
DCM (5 mL) and cooled to 0°C. A suspension of amine 335 (100 mg, 0.218 mmol) in DCM (2 mL) was 
added at 0°C, the cooling was removed and the reaction mixture stirred at RT overnight. Solvents were 
evaporated and the crude product purified by flash chromatography (silica gel, DCM/MeOH/Et3N 
96:3:1). Remaining Et3N after evaporating the appropriate fractions was removed by dissolving in sat. aq. 
NaHCO3 (2 mL) and extracting with DCM (3 x 2 mL). The DCM layers were dried over Na2SO4 and 
evaporated to give probe 6 (15 mg, 11%) as slightly brown oil. UV/Vis (PBS buffer): λmax abs. 296 nm. 
IR: 2927, 2361, 2161, 1653, 1598, 1539, 1282, 1176, 1024, 930 cm-1. 1H-NMR (300 MHz, CDCl3) δ 8.28 
(d, J = 8.2, 1H), 7.81 – 7.64 (m, 6H), 7.41 – 7.28 (m, 2H), 7.26 – 7.13 (m, 1H), 7.06 – 6.93 (m, 3H), 6.57 
(br, 1H), 4.72 (d, J = 2.4, 2H), 4.64 – 4.50 (m, 1H), 4.47 (t, J = 6.5, 2H), 3.48 (dd, J = 12.6, 6.4, 3H), 3.16 
(d, J = 8.9, 2H), 2.95 (q, J = 7.3, 4H), 2.61 – 2.37 (m, 6H), 2.34 – 2.20 (m, 2H), 1.29 (m, 5H). 13C-NMR 
(75 MHz, CDCl3) δ 194.6, 166.7, 161.8, 161.4, 140.8, 138.1, 137.2, 132.5, 130.4, 129.8, 127.2, 126.7, 
123.2, 123.0, 122.8, 114.7, 108.9, 77.7, 77.2, 76.3, 55.9, 51.5, 47.0, 46.0, 40.8, 40.4, 37.8, 32.8, 29.1, 
24.7, 14.2, 9.7. HRMS m/z calcd for C37H40N5O4 [M+H]
+ 618.3075, found 618.3069. 
7-(2-Hydroxyethoxy)-1-methyl-N-((1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1H-
indazole-3-carboxamide (8). Hydroxy indazole 731,35 (133 mg, 0.405 mmol) was dissolved in dry 
THF/DMF 5:1 (6 mL) and KOtBu (50 mg, 0.446 mmol) was added. The mixture was cooled to 0°C and 
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stirred for 30 min. (2-bromoethoxy)(tert-butyl)dimethylsilane (114 mg, 0.477 mmol) dissolved in dry 
THF (1.5 mL) was added, the cooling was removed and the reaction mixture stirred at RT overnight. 
Reaction control by TLC (silica gel, DCM/MeOH/Et3N 96:3:1) still indicated presence of starting 
material 7. More KOtBu (29 mg, 0.258 mmol) and TBS-protected bromide (46 mg, 0.192 mmol) were 
thus added and stirring at RT continued for 4 h. Solvents were removed under reduced pressure and the 
residue purified by flash chromatography (alumina, gradient DCM 100% to DCM/MeOH 99:1 and then 
DCM/MeOH 95:5) gave the TBS-protected alcohol (153 mg, 78%). 1H-NMR (300 MHz, CDCl3) δ 7.91 
(d, J = 8.2, 1H), 7.09 (t, J = 7.9, 1H), 6.72 (m, 2H), 4.64 – 4.42 (m, 1H), 4.32 (s, 3H), 4.18 (t, J = 4.9, 
2H), 4.03 (t, J = 4.9, 2H), 3.07 (d, J = 10.4, 2H), 2.59 – 2.42 (m, 5H), 2.00 – 1.89 (m, 3H), 1.49 (m, 1H), 
1.35 (t, J = 12.4, 2H), 1.04 (d, J = 8.4, 2H), 0.84 (s, 9H), 0.08 (s, 6H). 13C-NMR (75 MHz, CDCl3) δ 
162.0, 145.4, 137.3, 133.0, 125.2, 123.2, 115.0, 106.7, 69.9, 61.6, 51.3, 40.7, 39.5, 36.4, 33.1, 31.4, 25.8, 
24.9, 18.3, 14.3, -5.4. HRMS m/z calcd for C26H43N4O3Si [M+H]
+ 487.3099, found 487.3091. 
To a solution of TBS-protected alcohol from above (153 mg, 0.315 mmol) in THF (5 mL) was 
added a solution of TBAF (165 mg, 0.631 mmol) in THF (1 mL). The reaction mixture was stirred at RT 
for 2 d. H2O (15 mL) and 2M aq. NaOH (5 mL) were added and the solution extracted with DCM (4 x 20 
mL). The organic layers were dried (Na2SO4) and reduced in vacuo. Flash chromatography (alumina, 
gradient DCM 100% to DCM/MeOH 19:1) of the residue gave title alcohol 8 (60 mg, 51%). 1H-NMR 
(300 MHz, CDCl3) δ 7.80 (d, J = 8.2, 1H), 6.96 (t, J = 7.9, 1H), 6.68 (d, J = 8.4, 1H), 6.56 (d, J = 7.5, 
1H), 4.54 – 4.35 (m, 1H), 4.19 (s, 3H), 4.14 – 4.07 (m, 2H), 4.01 – 3.88 (m, 2H), 2.99 (d, J = 10.6, 2H), 
2.51 – 2.34 (m, 5H), 1.89 – 1.80 (m, 3H), 1.43 (m, 1H), 1.31 – 1.19 (m, 2H), 0.95 (d, J = 9.8, 2H). One 
proton was not detected due to rapid exchange. HRMS m/z calcd for C20H29N4O3 [M+H]
+ 373.2234, 
found 373.2242. 
7-(3-Hydroxypropoxy)-1-methyl-N-((1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1H-
indazole-3-carboxamide (9). This was synthesized according to the procedure for 8, using 731,35 (116 mg, 
0.353 mmol), KOtBu (44 mg, 0.392 mmol) and (3-bromopropoxy)(tert-butyl)dimethylsilane (107 mg, 
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0.423 mmol). Aqueous work up with H2O (10 mL) and DCM (3 x 15 mL) gave the crude product which 
was purified by flash chromatography (silica gel, DCM/MeOH/Et3N 96:3:1). Residual Et3N in the product 
was removed by extraction (DCM/H2O) and yielded TBS-protected alcohol (60.7 mg, 34%) as yellowish 
solid. 1H-NMR (300 MHz, CDCl3) δ 7.91 – 7.84 (m, 1H), 7.06 (t, J = 7.9, 1H), 6.74 – 6.64 (m, 2H), 4.60 
– 4.40 (m, 1H), 4.27 (s, 3H), 4.17 (t, J = 6.1, 2H), 3.81 (t, J = 6.1, 2H), 3.05 (d, J = 10.5, 2H), 2.56 – 2.39 
(m, 5H), 2.05 (p, J = 6.1, 2H), 1.92 (dd, J = 10.6, 3.4, 3H), 1.53 – 1.41 (m, 1H), 1.41 – 1.26 (m, 2H), 1.02 
(d, J = 9.6, 2H), 0.84 (s, 9H), 0.00 (s, 6H). HRMS m/z calcd for C27H45N4O3Si [M+H]
+ 501.3255, found 
501.3256. 
Following the procedure for 8, TBS-deprotection was carried out using protected alcohol from 
above (60 mg, 0.120 mmol) and TBAF (63 mg, 0.240 mmol). Flash chromatography of the crude product 
(alumina, gradient DCM 100% to DCM/MeOH 19:1) gave title alcohol 9 (39.5 mg, 85%). 1H-NMR (300 
MHz, CDCl3) δ 7.82 (d, J = 7.8, 1H), 7.00 (t, J = 7.9, 1H), 6.71 – 6.57 (m, 2H), 4.53 – 4.36 (m, 1H), 4.21 
(s, 3H), 4.16 (t, J = 6.0, 2H), 3.82 (t, J = 6.1, 2H), 2.99 (d, J = 10.6, 2H), 2.51 – 2.33 (m, 5H), 2.06 (quin, 
J = 6.1, 2H), 1.95 – 1.77 (m, 3H), 1.42 (d, J = 5.5, 1H), 1.34 – 1.20 (m, 2H), 0.96 (d, J = 9.9, 2H). One 
proton was not detected due to rapid exchange. 
7-(3-((4-Benzoylbenzyl)oxy)propoxy)-1-methyl-N-((1R,3r,5S)-9-methyl-9-
azabicyclo[3.3.1]nonan-3-yl)-1H-indazole-3-carboxamide (10). Alcohol 9 (19.7 mg, 51.1 µmol) was 
dissolved in dry THF/DMF 5:1 (3.5 mL), cooled to 0°C and NaH (9 mg, 225 µmol) was added. After 
stirring for 5 min at 0°C bromide 17 (21 mg, 76 µmol) was added in one portion, the cooling was 
removed and the reaction mixture stirred at RT overnight. The solvent were removed in vacuo and the 
residue purified by prepTLC (silica gel, DCM/MeOH/Et3N 96:3:1). Et3N contaminating the product was 
removed by aqueous extraction (DCM/H2O) and finally gave probe 10 (5.9 mg, 20%) as yellowish solid. 
IR: 2923, 2855, 2361, 1654, 1532, 1507, 1258, 1113, 735, 701, 631 cm-1. 1H-NMR (300 MHz, CDCl3) δ 
7.92 (d, J = 7.7, 1H), 7.80 – 7.70 (m, 4H), 7.63 – 7.55 (m, 1H), 7.52 – 7.40 (m, 4H), 7.10 (t, J = 7.9, 1H), 
6.79 – 6.70 (m, 2H), 4.62 (s, 2H), 4.60 – 4.44 (m, 1H), 4.30 – 4.19 (m, 5H), 3.75 (t, J = 6.1, 2H), 3.11 (d, 
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J = 10.5, 2H), 2.60 – 2.44 (m, 5H), 2.28 – 2.16 (m, 2H), 2.02 – 1.91 (m, 3H), 1.55 – 1.47 (m, 1H), 1.44 – 
1.32 (m, 2H), 1.07 (d, J = 9.9, 2H). 13C-NMR (75 MHz, CDCl3) δ 196.3, 162.0, 145.4, 143.0, 137.6, 
137.3, 136.9, 132.8, 132.4, 130.3, 130.0, 128.3, 127.1, 125.2, 123.3, 114.9, 106.2, 77.2, 72.5, 67.0, 65.1, 
51.4, 40.6, 39.5, 32.9, 29.7, 29.7, 25.0, 14.3. HRMS m/z calcd for C35H41N4O4 [M+H]
+ 581.3122, found 
581.3122. 
1-Methyl-N-((1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-7-(2-((4-(3-(trifluoromethyl)-
3H-diazirin-3-yl)benzyl)oxy)ethoxy)-1H-indazole-3-carboxamide (11). This was obtained following 
the procedure for 10, using alcohol 8 (30 mg, 80.6 µmol), NaH (10 mg, 250 µmol) and diazirine bromide 
19 (40 mg, 100 µmol). The crude product was purified by prepTLC (silica gel, DCM/MeOH/Et3N 96:3:1) 
and residual Et3N removed from the product by aqueous extraction (DCM/H2O). This yielded probe 11 
(16.1 mg, 35%). IR: 2924, 2864, 2358, 2161, 2029, 1977, 1653, 1533, 1258, 1153, 938, 668 cm-1. 1H-
NMR (300 MHz, CDCl3) δ 7.87 (d, J = 7.8, 1H), 7.31 (d, J = 8.5, 2H), 7.11 (d, J = 8.1, 2H), 7.07 – 6.99 
(m, 1H), 6.69 (d, J = 8.4, 1H), 6.64 (d, J = 7.5, 1H), 4.56 (s, 2H), 4.52 – 4.40 (m, 1H), 4.29 – 4.16 (m, 
5H), 3.89 – 3.81 (m, 2H), 3.04 (d, J = 10.1, 2H), 2.54 – 2.37 (m, 5H), 1.96 – 1.84 (m, 3H), 1.46 (d, J = 
5.8, 1H), 1.40 – 1.23 (m, 2H), 1.00 (d, J = 9.2, 2H). 13C-NMR (75 MHz, CDCl3) δ 177.1, 162.1, 145.3, 
139.9, 137.51, 133.1, 128.8, 128.0, 126.8, 125.4, 123.3, 115.5, 106.8, 77.4, 72.7, 68.9, 67.8, 51.5, 40.8, 
39.6, 33.2, 25.1, 14.5. HRMS m/z calcd for C29H34F3N6O3 [M+H]
+ 571.2639, found 571.2640. 
(1R,3r,5S)-9-(4-(3-(Trifluoromethyl)-3H-diazirin-3-yl)benzyl)-9-azabicyclo[3.3.1]nonan-3-
amine (13). Granatane 1240 (30 mg, 0.125 mmol) was dissolved in EtOH (4 mL) and K2CO3 (35 mg, 
0.253 mmol) and diazirine iodide 21 (40 mg, 0.098 mmol) were added. The suspension was first stirred at 
RT overnight and then heated at 55°C for 3.5 h. The solvent was reduced to about 2 mL in vacuo, DCM 
(10 mL) was added and the mixture extracted with H2O. The water phases were washed with DCM (2 x 
10 mL). The combined organic layers were dried over Na2SO4 and evaporated. The crude product was 
purified by flash chromatography (silica gel, gradient hexanes 100% to hexanes/EtOAc 99:1 to 
hexanes/EtOAc 7:3) and gave the N-alkylated granatane (36 mg, 82%). 1H-NMR (300 MHz, CDCl3) δ 
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7.31 (d, J = 6.9, 2H), 7.05 (d, J = 7.3, 2H), 4.22 (s, 1H), 4.01 (s, 1H), 3.73 (s, 2H), 2.95 (d, J = 10.5, 2H), 
2.29 (dd, J = 17.9, 12.0, 2H), 1.83 (d, J = 2.9, 3H), 1.39 (s, 9H), 1.22 (s, 1H), 1.08 (t, J = 12.6, 2H), 0.93 
(d, J = 10.1, 2H). 13C-NMR (75 MHz, CDCl3) δ 142.5, 128.6, 127.4, 126.4, 79.1, 77.2, 55.4, 49.4, 33.9, 
29.7, 28.5, 24.8, 14.2, 14.1. HRMS m/z calcd for C22H30F3N4O2 [M+H]
+ 439.2315, found 439.2316. 
To a solution of Boc-protected granatane from above (30 mg, 0.068 mmol) in DCM (1 mL) was 
added TFA (0.25 mL) and the reaction mixture stirred at RT for 6 h. The volatiles were removed in 
vacuo, the residue taken up in DCM (6 mL) and extracted with sat. aq. NaHCO3 (3 mL). The aqueous 
phase was extracted with DCM (3 x 4 mL), the combined organic layers dried over Na2SO4 and 
evaporated. This gave title compound 13 (24.5 mg, quant.). 1H-NMR (300 MHz, CDCl3) δ 7.29 (d, J = 
8.5, 2H), 7.05 (d, J = 8.0, 2H), 3.74 (s, 2H), 3.33 – 3.16 (m, 1H), 2.92 (d, J = 11.4, 2H), 2.18 (td, J = 11.2, 
5.7, 2H), 1.93 – 1.72 (m, 3H), 1.48 – 1.38 (m, 1H), 1.12 – 0.99 (m, 2H), 0.94 (d, J = 12.9, 2H). Two 
protons (amine) were not observed due to rapid exchange. 13C-NMR (75 MHz, CDCl3) δ 142.9, 128.5, 
127.4, 126.3, 122.2 (q, J = 274.7), 55.4, 49.6, 43.0, 37.3, 29.7, 24.9, 14.2. HRMS m/z calcd for 
C17H22F3N4 [M+H]
+ 339.1791, found 339.1780. 
N-((1R,3r,5S)-9-(4-(3-(Trifluoromethyl)-3H-diazirin-3-yl)benzyl)-9-azabicyclo[3.3.1]nonan-3-
yl)-1H-indazole-3-carboxamide (14). Indazole-3-carboxylic acid (19.4 mg, 0.12 mmol), DCC (27.4 mg, 
0.133 mmol) and HOBt (15 mg, 0.111 mmol) were dried in high-vacuum for 20 min and then dissolved 
under dry conditions in DCM/DMF 3:2 (5 mL). After stirring the solution for 2 h at RT, granatane 13 
(22.8 mg, 0.067 mmol) dissolved in DCM (3 mL) was added dropwise and the reaction mixture stirred at 
RT overnight. The solvents were removed under reduced pressure, the residue dissolved in DCM (5 mL) 
and extracted with sat. aq. NaHCO3 (3 mL). The aqueous phase was extracted with DCM (3 x 6 mL), the 
combined organic layers dried (Na2SO4) and evaporated. The crude product was purified by flash 
chromatography (silica gel, DCM/MeOH/Et3N 96:3:1) and prepHPLC (reverse phase, gradient H2O 100% 
+ 0.1% TFA to H2O/MeCN 4:6 + 0.1% TFA to MeCN 100% + 0.1% TFA, tR (product) = 28 min). The 
fractions were lyophilized, the isolated TFA salt dissolved in H2O (1 mL) and extracted into CHCl3 (3 
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mL). Evaporation of the organic phase gave indazole carboxamide 14 (21.6 mg, 66%). 1H-NMR (300 
MHz, CDCl3) δ 10.78 (br, 1H), 8.37 (d, J = 8.1, 1H), 7.45 (d, J = 8.4, 1H), 7.40 – 7.29 (m, 3H), 7.28 – 
7.19 (m, 1H), 7.04 (d, J = 8.0, 2H), 6.83 (d, J = 8.7, 1H), 4.71 – 4.45 (m, 1H), 3.77 (s, 2H), 3.00 (d, J = 
11.1, 2H), 2.41 (td, J = 11.9, 6.2, 2H), 1.94 – 1.80 (m, 3H), 1.49 (d, J = 9.4, 1H), 1.35 – 1.21 (m, 2H), 
0.97 (d, J = 10.9, 2H). 13C-NMR (75 MHz, CDCl3) δ 162.3, 157.1, 142.5, 141.5, 139.5, 128.7, 127.5, 
127.2, 126.4, 122.7 (d, J = 2.7), 122.2 (q, J = 274.3), 122.0, 109.9, 55.5, 53.4, 49.3 (d, J = 7.7), 41.3, 33.9, 
33.5, 28.1, 25.6, 24.9 (d, J = 6.6), 14.2. HRMS m/z calcd for C25H26F3N6O [M+H]
+ 483.2115, found 
483.2100. 
1-methyl-N-((1R,3r,5S)-9-(4-(3-(Trifluoromethyl)-3H-diazirin-3-yl)benzyl)-9-
azabicyclo[3.3.1]nonan-3-yl)-1H-indazole-3-carboxamide (15). Indazole carboxamide 14 (16 mg, 
0.033 mmol) was dissolved in THF/DMF 4:1 (3 mL), KOtBu (5 mg, 0.043 mmol) and MeI (15 mg, 1.06 
mmol) were added and the reaction mixture stirred at RT overnight. Solvents were removed under 
reduced pressure and the residue taken up in EtOAc (7 mL). This was extracted with sat. aq. NaCl (3 
mL), sat. aq. NaHCO3 (3 mL) sat. aq. NH4Cl (3 mL) and finally sat. aq. NaCl (3 mL). The organic layer 
was dried over Na2SO4 and evaporated yielding probe 15 (14.5 mg, 88%). UV/Vis (PBS buffer): λmax abs. 
327 nm. 1H-NMR (300 MHz, CDCl3) δ 8.39 – 8.27 (m, 1H), 7.41 – 7.32 (m, 4H), 7.25 – 7.20 (m, 1H), 
7.07 (d, J = 7.9, 2H), 6.73 (d, J = 8.7, 1H), 4.70 – 4.49 (m, 1H), 4.02 (s, 3H), 3.80 (s, 2H), 3.03 (d, J = 
11.2, 2H), 2.43 (td, J = 12.1, 6.4, 2H), 2.01 – 1.77 (m, 3H), 1.53 (br, 1H), 1.39 – 1.25 (m, 2H), 1.00 (d, J 
= 13.0, 2H). 13C-NMR (100 MHz, CD3OD) δ 164.1, 141.9, 128.1, 126.8, 126.2, 125.8, 122.4, 122.0, 
108.4, 54.8, 48.8, 40.5, 35.3, 32.9, 24.2, 20.5, 15.4. HRMS m/z calcd for C26H28F3N6O [M+H]
+ 497.2271, 
found 497.2262. 
1-(Prop-2-yn-1-yl)-N-((1R,3r,5S)-9-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzyl)-9-
azabicyclo[3.3.1]nonan-3-yl)-1H-indazole-3-carboxamide (16). Indazole carboxamide 14 (24 mg, 0.05 
mmol) was dissolved in DMF (1 mL) under dry conditions, Cs2CO3 (42.7 mg, 0.131 mmol) was added 
and the solution stirred at RT 20 min. 3-Bromoprop-1-yne (8.2 mg, 0.068 mmol) was added and the 
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reaction mixture stirred at RT for 4 h. Solvents were removed in vacuo, sat. aq. NaHCO3 (5 mL) was 
added and extracted with DCM (3 x 20 mL). The combined organic layers were dried (Na2SO4) and 
evaporated to give probe 16 (24.2 mg, 93%). UV/Vis (PBS buffer): λmax abs. 316 nm. IR: 3309, 2926, 
2359, 2343, 1642, 1539, 1343, 1311, 1231, 1181, 1154, 937 cm-1. 1H-NMR (300 MHz, DMSO-d6) δ 8.22 
(d, J = 8.1, 1H), 8.15 (d, J = 9.1, 1H), 7.81 (d, J = 8.5, 1H), 7.52 (m, 3H), 7.34 (d, J = 7.3, 1H), 7.29 (d, J 
= 8.6, 2H), 5.58 (d, J = 7.8, 1H), 5.44 (d, J = 2.4, 2H), 4.58 – 4.42 (m, 1H), 3.89 (s, 2H), 3.02 (d, J = 10.8, 
2H), 2.26 – 2.11 (m, 3H), 1.92 (t, J = 14.1, 2H), 1.80 – 1.40 (m, 4H), 1.00 (d, J = 15.8, 2H). 1H-NMR 
(300 MHz, CDCl3) δ 8.36 (d, J = 8.2, 2H), 7.49 (d, J = 8.5, 1H), 7.36 – 7.41 (m, 3H), 7.25 (m, 1H), 7.07 
(d, J = 8.0, 2H), 6.73 (d, J = 8.7, 1H), 5.12 (d, J = 2.5, 2H), 4.67 – 4.52 (m, 1H), 4.02 (d, J = 7.9, 1H), 
3.48 – 3.34 (m, 1H), 3.03 (d, J = 10.9, 2H), 2.52 – 2.39 (m, 2H), 2.37 (t, J = 2.5, 1H), 1.94 – 1.80 (m, 
2H), 1.68 – 1.45 (m, 2H), 1.40 – 1.28 (m, 2H), 1.03 – 0.93 (m, 2H). 13C-NMR (75 MHz, CDCl3) δ 161.7, 
156.7, 142.5, 140.6, 138.5, 128.7, 127.4, 126.5, 123.5, 122.9, 120.4, 109.4, 77.2, 76.5, 74.3, 55.5, 49.3, 
41.2, 39.4, 34.0, 33.5, 25.6, 24.9, 14.3. 19F-NMR (376 MHz, DMSO-d6) δ -64.6. HRMS m/z calcd for 
C28H28F3N6O [M+H]
+ 521.2271, found 521.2267. 
Biology. Materials, human embryonic kidney (HEK) 293T cell culture maintenance, 5-HT3 
receptor expression, 5-HT3 receptor affinity purification and its micelle-solubilization, radioligand 
binding and binding data analysis were described previously.32 
Photo-crosslinking 5-HT3 receptor with granisetron probes. For all irradiation experiments a 
UVP 3UVTM – 38 UV Lamp (Upland, CA, USA) was used and set to an irradiation wavelength of 302 nm 
(lamp power: 8W).  
For whole cell lysate experiments, HEK293T cells stably expressing human N-terminal FLAG-
tagged 5-HT3A receptor
32 were defrosted (1.8 mL) and 2 mL PBS buffer (50 mM NaCl, 0.27 mM KCl, 1 
mM Na2HPO4, 0.2 mM KH2PO4, pH 7.4), 75 µL Halt
TM Protease Inhibitor Cocktail (1x, Thermo Fisher 
Scientific), 5 µL CyanaseTM Nuclease (50 U/µL, RiboSolutions Inc.) and 5 µL MnSO4 (1 M) was added. 
The cells were homogenized using a Dounce homogenizer, and by aspiration with a syringe through a 
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21G needle and expulsion through a 27G needle. 5-HT3 receptor-containing whole cell lysate (250 µL) 
prepared in this way was incubated either with 2.5 µL 6 (25 mM in DMSO), 2.5 µL 16 (25 mM in 
DMSO) or 2.5 µL 22 (50 mM in DMSO) at RT for 90 min in the dark and then irradiated on ice for 30 
min in a 9-well plate. The solutions were transferred back to tubes and 250 µL PBS was added. 
To determine concentration dependence of photo-crosslinking with 6, a solution of purified, 
micelle-solubilized FLAG-tagged h5-HT3A receptor was adjusted to a concentration of 8.4 µg/mL using 
PBS buffer + 0.4 mM C12E9. In a 48-well plate, 5-HT3 receptor-micelle solutions (100 µL) were mixed 
each with 1 µL of different stock solutions of either 6 or 22 in order to obtain final compound 
concentrations of 2.5 µM, 250 nM, 25 nM and 2.5 nM. The solutions were incubated in the dark for 30 
min at RT and then irradiated on ice for 30 min. The samples were diluted with 50 µL PBS and 
transferred back from the wells into tubes.  
For competition experiments with granisetron, a solution of purified, micelle-solubilized FLAG-
tagged h5-HT3A receptor was adjusted to a concentration of 50 µg/mL using PBS buffer + 0.4 mM C12E9. 
Using a 48-well plate, 100 µL of this 5-HT3 receptor-micelle solution was mixed with 0.5 µL granisetron 
(2.5 mM in DMSO) and incubated for 10 min at RT. Subsequently, either 0.5 µL 6 (25 mM in DMSO) or 
0.5 µL 22 (50 mM) was added and the samples incubated for further 30 min in the dark at RT. The 
samples were then irradiated on ice for 20 min, diluted with PBS (50 µL) and transferred back to tubes. 
For live cells irradiation experiments, HEK293T cells stably expressing human N-terminal FLAG-
tagged 5-HT3A receptor were grown to approximately 80% density in four T300 plates. The cells were 
washed with PBS (10 mL/plate), then incubated with PBS (10 mL/plate) for 10 min at 37°C and detached 
by repeatedly flushing them off. The cell suspension was cooled on ice, 300 µL HaltTM Protease Inhibitor 
Cocktail added and split into two portions to which probes 6 or 22 were added (100 µL, 0.5 mM in 
DMSO). The suspensions were incubated for 15 min at RT in the dark and then irradiated in a 6-well 
plate on ice for 25 min while gently stirring the cells. The viability of the cells was monitored during 
irradiation (t = 0, 10, 20, 25 min) by using a cell counter (Countess automated cell counter, Invitrogen) 
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and is depicted in Figure S2. For each cell suspension portion (with either 6 or 22), the cells were pelleted 
by centrifugation (5 min, 500g), the supernatant discarded and the volume increased to 3 mL with PBS 
buffer. More protease inhibitor cocktail was added (75 µL) and the cells were homogenized first using a 5 
mL-douncer, and then by aspiration with a syringe through a 21G needle and expulsion through a 27G 
needle. The membranes were collected by centrifugation at 100,000g for 30 min, pellets resuspended in 5 
mL solubilization buffer (10 mM phosphate buffer, pH 7.4, 0.5 M NaCl, 10 mM imidazole, 2 mM C12E9) 
and 2.5 µL Cyanase (50 U/mL) and 2.5 µL MnSO4 (1 mM) were added. The samples were agitated for 1 
h at 4°C and then centrifuged (1 h, 100,000g) to remove insoluble components. The supernatant was 
incubated head-over-tail with 100 µL prewashed FLAG beads (FLAG M2 agarose beads, Sigma) for 2 h 
at 4°C. The beads were removed by centrifugation (2 min, 500g), washed 5 times with PBS buffer 
containing 0.4 mM C12E9 and incubated with 125 µL elution buffer (wash buffer supplemented with 1 
mg/mL FLAG peptide). The suspension was centrifuged (2 min, 500g) through Micro Bio-Spin columns 
and gave the eluate. 
Conjugation with biotin tag via CuAAC. Stock solutions of click reagents biotin-PEG2-azide 23 
(5 mM in DMSO), TCEP (50 mM in H2O, freshly prepared prior to each experiment), TBTA (1.7 mM in 
t-BuOH/DMSO 4:1) and CuSO4·5 H2O (50 mM in H2O) were prepared and added in this order to a tube 
containing alkynylated protein sample obtained from photo-crosslinking with either 6, 16 or 22. A ratio of 
photo-crosslinking probe/biotin azide/TCEP/TBTA/CuSO4 of 1:1000:1000:3000:1000 was normally used 
and the tube vortexed after addition of each click reagent. The mixture was incubated for 2 h at RT on a 
vertical rotator and subsequently transferred to a Slide-A-Lyzer® MINI Dialysis device (Thermo Fisher, 
0.5 mL, 20K MWCO).  The protein reaction mixture was dialyzed against PBS buffer (13.5 mL, twice for 
2 h at RT, then overnight at 4°C). For biotin pull-down, PBS buffer pre-washed (2 x 25 µL) Dynabeads® 
MyOneTM Streptavidin M 270 (Life TechnologiesTM) were transferred with PBS (50 µL) to the dialyzed 
eluate and incubated overnight. The beads were collected by means of magnet and the supernatant 
removed. The streptavidin beads were washed with 1 mL C12E9 solution (2 mM in PBS), then PBS (3 x 1 
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mL) and incubated with 80 µL LDS loading buffer (containing 2 mM biotin) for 10 min at 95°C for SDS 
gel analysis. 
Western blot. The protein samples from irradiation and subsequent biotinylation experiments were 
loaded and run on a SDS-PAGE gel. Protein bands were transferred to a membrane using iBlot® Novex® 
Gel Transfer Stacks. Membranes were blocked for 30 min with SeaBlock blocking buffer at RT and then 
incubated with IRDye 800CW streptavidin (Li-Cor®, diluted 1:10000 in Seablock buffer + 0.2% SDS) for 
30 min. The membranes were washed with TBS-Tween buffer (5 x 5 min), then blocked with TBS-Tween 
milk (0.1% Tween-20, 5% skim milk powder) for 30 min and incubated with rabbit α-FLAG (Bethyl 
Laboratories, diluted 1:2000 in TBS-Tween milk) overnight at 4°C. Membranes were rinsed with TBS-
Tween (5 x 5 min) and then incubated with donkey α-rabbit IRDye 680 (Li-Cor®, diluted 1:10000 in 
TBS-Tween milk) for 2 h at RT. The membranes were rinsed with TBS-Tween (5 x 5 min), dried and 
then imaged using a Li-Cor® Odyssey® Fluorescent Imaging System. 
Protein Mass Spectrometry. Protein mixtures from photo-crosslinking experiments were run on a 
SDS-PAGE gel, the gel was fixed for 10 min with H2O/MeOH/AcOH 5:4:1, washed with H2O (3 x 5 
min) and then stained with Colloidal Coomassie for 2 h. The gel was rinsed with H2O for 1 h and protein 
bands between 50 and 60 kDa cut out under sterile conditions. Gel cubes were washed with 50 mM 
Tris/HCl pH 8 (Tris buffer) and Tris buffer/MeCN 50:50 before disulphide reduction with 50 mM DTT 
(Fluka, Buchs, Switzerland) in Tris buffer for 30 min at 37°C and subsequent thiol alkylation with 50 mM 
iodoacetamide (Fluka) in Tris buffer for 30 min at 37°C in the dark. After washing with Tris buffer and 
dehydration with MeCN the gel cubes were soaked with trypsin solution composed of 10 ng/µL trypsin 
(Promega) in 20 mM Tris/HCl pH 8 + 0.01% ProteaseMax (Promega) for 30 min on ice. Gel cubes were 
subsequently covered with 5-10 mL of 20 mM Tris/HCl before digestion for 1 h at 50°C. For digestions 
with Proteinase K (1 ng/µL and 10 ng/µL, Promega), AspN (10 ng/µL, Roche) and LysC/trypsin mix (10 
ng/µL, Promega), ProteaseMax was not included in the digestion buffer, and incubations were 30 min on 
ice + 30 min at 37°C, 6 h at 37°C and 16 h at RT, respectively. The supernatant liquid was combined with 
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a single gel extract performed with 20 mL 20% (v/v) formic acid (Merck) in polypropylene HPLC vials 
and 5 µL was analyzed by LC-MS/MS (PROXEON coupled to a QExactive mass spectrometer, 
ThermoFisher Scientific). 
Peptides were trapped on an µPrecolumn C18 PepMap100 (5 µm, 100 Å, 300 µm x 5 mm, 
ThermoFisher Scientific, Reinach, Switzerland) and separated by backflush on a C18 column (3 µm, 100 
Å, 75 µm x 15 cm, Nikkyo Technos, Tokyo, Japan) by applying a 30 min gradient of 5% to 40% MeCN 
in H2O, 0.1% formic acid, at a flow rate of 300 nL/min. Peptides of m/z 360-1400 were detected on the 
QExactive with resolution set at 70,000 with and automatic gain control (AGC) target of 1E06 and 
maximum ion injection time of 50 ms. A top ten data dependent method for precursor ion fragmentation 
was applied with the following settings: resolution 17,500, AGC of 1E05, maximum ion time of 110 ms, 
mass window 2 m/z, collision energy 27, underfill ratio 1%, charge exclusion of unassigned and 1+ ions, 
peptide match on, respectively. 
Fragment spectra information was extracted into mgf file format using ProteomeDiscoverer v1.3 
software (ThermoFisher Scientific). Fragment spectra interpretation was performed with 
ProteomeDiscoverer v1.3 against human database, using fixed modifications of carbamidomethylation on 
cysteine, and variable modifications of oxidation on methionine, acetylation on protein N-terminal and 
photo-crosslinking probes on certain amino acids. Protein identifications were considered with at least 
two unique peptides identified at a 1% FDR on the level of peptide spectrum matches. Fragment peptide 
sequences were identified with the Sequest HT (v1.3) search engine implemented in the 
ProteomeDiscoverer software. 
Molecular Modelling. Homologous AChBP chimera bound with granisetron (PDB ID: 2YME) 
was used as a protein template for the docking. This chimera, termed 5HTBP, has substitutions in the 
orthosteric binding site that mimic the 5-HT3 receptor.
14 The ligands 4 and 10 were constructed ab initio 
in Chem3D Pro v14.0 (PerkinElmer, Waltham, MA), based on the crystal structure of granisetron 
extracted from the Cambridge Structural Database (CSD ID: KUQDAC), and energy-minimized using the 
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included MM2 force field. A library of 200 conformers was generated for each ligand using OMEGA 
v2.5 (OpenEye Scientific Software, Santa Fe, NM). To generate a docking template from the 2YME 
crystal structure, FRED RECEPTOR v2.2.5 (OpenEye Scientific Software) was utilized, whereby the 
ligand binding site was defined as a box of V = 5143 Å3 around the bound granisetron. The constructed 
ligands were docked into this binding site template, in order to predict their binding poses, using FRED 
v2.1 (OpenEye Scientific Software) that utilizes an exhaustive process to position and score all 
conformers of a ligand at all possible positions within the defined binding site. For each ligand, ten 
docking poses were generated and ranked using the inbuilt Chemgauss3 scoring function. The proposed 
binding poses were visualized with PyMOL v1.7 (Schrödinger LLC, Portland, OR). 
 
Associated Content 
Supporting Information 
Chemistry general procedures and synthesis of photo-crosslinking moieties. Whole cell lysate photo-
crosslinking. MS sequence coverage of 5-HT3A receptor with different digestion protocols. MS/MS of 
oxidized loop C peptide fragments photo-crosslinked with 4 and 10. Docking of granisetron into 5HTBP. 
Alternative docking poses for 4 and 10. Copies of NMR spectra of final compounds. This material is 
available free of charge via the internet at http://pubs.acs.org. 
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AChBP, acetylcholine binding protein; CuAAC, Cu(I)-catalyzed alkyne-azide cycloaddition; ECD, 
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bowel syndrome; ICD, intracellular domain; nACh, nicotinic acetylcholine (receptor); PET, positron 
emission tomography; P-PALM, post-photoaffinity modification; SAR, structure-activity relationship; 
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